2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Arun Azad, PhD, discusses the utility of adding enzalutamide to androgen deprivation therapy in subgroups of men with metastatic hormone-sensitive prostate cancer.
Arun Azad, PhD, an associate professor at Peter MacCallum Cancer Centre and the University of Melbourne; fellow at Victorian Cancer Agency; and chair of the ANZUP Cancer Trials Group Translational, discusses the utility of adding enzalutamide (Xtandi) to androgen deprivation therapy (ADT) in subgroups of men with metastatic hormone-sensitive prostate cancer (mHSPC).
Two pivotal studies have demonstrated the benefit of adding enzalutamide to ADT in patients with mHSPC, says Azad. The phase 3 ARCHES study examined ADT plus or minus enzalutamide in men with mHSPC. This trial included patients with low-volume and high-volume metastatic, newly diagnosed, and relapsed metastatic disease. The primary end point of the trial was radiographic progression-free survival.
The study met its primary end point, showing a significant benefit with the addition of enzalutamide to ADT across all patient subgroups analyzed, concludes Azad.